桂枝茯苓丸联合宫腔镜下输卵管介入再通术治疗瘀血内阻型输卵管阻塞性不孕症临床研究  

A clinical study of Guizhi-Fuling pill combined with conventional therapy for the patients with oviduct obstructive infertility

作　　者：刘静[1] 王静[1] 曲红卫 慕建宁[1] 卢占斌[1] Liu Jing;Wang Jing;Qu Hongwei;Mu Jianning;Lu Zhanbin(Department of Gynaecology,Xi＇an Gaoxin Hospital,Xi＇an 710000,China)

机构地区：[1]陕西省西安高新医院妇科,710000

出　　处：《国际中医中药杂志》2018年第9期814-817,共4页International Journal of Traditional Chinese Medicine

基　　金：陕西省教育厅自然科学研究项目（2013JK0782）

摘　　要：目的 评价桂枝茯苓丸联合宫腔镜下输卵管介入再通术治疗输卵管阻塞性不孕症（oviduct obstructive infertility, OOI）的疗效。方法 将符合入选标准的102例OOI患者按就诊顺序随机分为2组，研究过程中脱落5例，最终治疗组完成49例、对照组完成48例。对照组给予宫腔镜下输卵管介入再通术，治疗组在对照组基础上于术后第2天起服用桂枝茯苓丸。2组均15 d为1个疗程，2个疗程后可试孕，受孕者停药，未孕者连用6个疗程。分别于治疗前后进行中医症状评分，采用放射免疫法测定IL-6水平；术后6个月行子宫输卵管通液检查，记录治疗期间及随访12个月的妊娠情况。结果 治疗后，治疗组经来腹痛程度[（0.6±0.1）分比（1.3±0.1）分，t=3.612]、腰痛[（0.9±0.1）分比（1.6±0.2）分，t=2.553]、坠胀不适[（0.5±0.0）分比（1.0±0.8）分，t=2.364]、经血中血块[（0.5±0.1）分比（1.0±0.1）分，t=2.331]评分均低于对照组（P＜0.05）。治疗后，治疗组输卵管通畅率为75.5%（37/49）、对照组为50.0%（24/48），2组比较差异有统计学意义（χ2=8.075，P=0.044）。治疗期间至随访结束，治疗组妊娠率为63.3%（31/49）、对照组为37.5%（18/48），2组妊娠率比较差异有统计学意义（χ2=6.724，P=0.035）。治疗后，治疗组血清IL-6[（31.04±2.47）ng/ml比（42.71±2.52）ng/ml，t=7.593]水平低于对照组（P＜0.05）。结论 桂枝茯苓丸联合宫腔镜下输卵管介入再通术可降低OOI患者IL-6水平、促进输卵管再通、提高宫内妊娠率，改善临床症状。Objective In order to evaluate the clinical curative effect of Guizhi-Fuling pill combined with conventional therapy for the patients with oviduct obstructive infertility. Methods In this study, 102 patients with oviduct obstructive infertility （OOI） that accorded with the inclusion criteria were randomly divided into two groups according to the order of treatment. During the study, a total of 5 patients were lost in the two groups, and so 49 in the treatment group and 48 in the control group completed the protocol. The control group was given fallopian tube recanalization under the hysteroscopy, and the treatment group was given oral Guizhi-Fuling pill at day 2 after surgery on the basis of the control group treatment. Both groups were observed for 6 months. Before and after treatment, TCM symptom score was conducted, and IL-6 level was determined by radioimmunoassay; the uterine fallopian tube was examined after the 6th month of treatment, and pregnancy rate was observed and recorded. Results After treatment, abdominal pain degree （0.6 ± 0.1 vs. 1.3 ± 0.1, t=3.612）, the low back pain （0.9 ± 0.2 vs. 1.6 ± 0.2, t=2.553）, abdominal distension （0.5 ± 0.0 vs. 1.0 ± 0.8, t=2.364）, menstrual blood clots （0.5 ± 0.1 vs. 1.0 ± 0.1, t=2.331） in the treatment group were significantly lower than those in the control group （Ps〈0.05）. After treatment, the rate of oviduct patency was 75.5% （37/49） in thetreatment group, 50.0% （24/48） in the control group, and the comparison difference between the two groups was statistically significant （χ2=8.075, P=0.044）. After 6 months of treatment, the pregnancy rate of the treatment group was 63.3% （31/49）, and that of the control group was 37.5% （18/48）, the difference of pregnancy rate between the two groups was statistically significant （χ2=6.724, P=0.035）. After treatment, serum IL-6 （31.04 ± 2.47 ng/ml vs. 42.71 ± 2.52 ng/ml, t=7.593） in the treatment group was signicantly lower than the control group （P〈0.05）. C

关 键 词：不育  女性 输卵管阻塞 桂枝茯苓丸 宫腔镜 介入性 

分 类 号：R711.6[医药卫生—妇产科学]